Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + ixazomib maintenance after autologous transplant in high-risk multiple myeloma
ChiCTR2000034299Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and ixazomib in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoint: CR + VGPR rate at 1 year. Started Jul 2020; status: recruiting.
02
Drugs
lenalidomideixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000034299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034299.